09/10/2026 Johnson & Johnson reported 2-year data for icotrokinra in plaque PsO Alumis reported new Phase 3 data for envudeucitinib in plaque PsO Johnson & Johnson reported 2-year data for icotrokinra in plaque PsO (Ref) Johnson & Johnson reported 2-year Phase 3, ICONIC-LEAD/ NCT06095115 data for ICOTYDE® (icotrokinra; IL-23 receptor antagonist) in patients aged ≥12 years with moderate-to-severe plaque psoriasis (PsO).  Endpoint Results Timepoint PASI 90 ≥72% At Wk 12 IGA 0/